NamWeb - the medicinal product information service is being improved by Mälkönen, Leila
Läkemedelsinformation från Läkemedelsverket, Finland  
Drug information from the National Agency for Medicines, Finland
5|2007
Lääketietoa Lääkelaitokselta
TABU 5.2007 |  15 årgången | 15th Annual volume
Editorial
ADR News
Vad skapar efterfrågan på olagliga eller förfalskade
läkemedel?
Jussi Holmalahti
Trombolysbehandling och vårdkedja vid hjärninfarkt
Markku Kaste 
Biverkningar hos äldre
Annikka Kalliokoski | Leena Sommarberg | Marja Forsell
Biverkningar på centrala nervsystemet av betalaktam-
antibiotika
Jani Penttilä
Läkemedelsverket påminner konsumenterna om 
vikten av att bedöma information på internet
Ulla Närhi| Anna Karjalainen
Guide för märkning av verksamma beståndsdelar i
växtbaserade läkemedel
Sari Koski
Biverkningar av immunologiska läkemedel för djur 2006
Tita-Maria Muhonen
What creates a demand for unlicensed or
adulterated medicines? 
Jussi Holmalahti
Stroke thrombolysis and the chain of recovery
Markku Kaste
Adverse drug reactions in the elderly
Annikka Kalliokoski | Leena Sommarberg | Marja Forsell
NamWeb – the medicinal product information service 
is being improved
32
33
38
43
45
47
49
51
52
58
63
På svenska | Översättning Mats Försskåhl
In English | Translation Mervi Moisander
Ledare
Om biverkningar
Växtbaserade läkemedel
Läkemedel för djur
TABU 5. 2007 51
In English
What creates a demand for unlicensed or 
adulterated medicines?
There are thousands of unlicensed operators trading
in medicines over the Internet, and it is impossible
to estimate the damage they have caused among pa-
tients. The medicinal products available on e-com-
merce are often stolen or fake products with con-
tents not always corresponding to what is promised.
According to an estimate by the World Health
Organisation (WHO), about ten percent of all medi-
cines sold on the world market are counterfeit drug.
It has been clearly demonstrated that illegal trade of
medicines is a branch of international criminal activ-
ity in which the operators are identical with those
dealing in narcotics and similar doping substances.
In the opinion of these operators, the economical
and legal risks associated with unlicensed trading in
medicines are minimal in comparison with narcotics
and doping agents. It would appear that we Finns
have lulled ourselves into false security with an illu-
sion of safe e-commerce in medicines.
In news reporting and media discussions the
terms legal and illegal medicinal products are con-
cepts which are becoming ever more relative. In the
course of such discussions, less guardianship and
more freedom are demanded; abandonment of the
imposed prescription status of medicines and allow-
ing their retail grocery shop and on-line sale. It
amounts to dreaming in public of how a customer
could by one opening of a door satisfy an increasing
number of needs. There is needs for a market place
which is always open, where in addition to alcohol,
beer and health food products also “simple over-the-
counter and self-medication products” would be on
offer as well. Simple medicines, however, have a
place only in the imaginary world.
The efficacy, safety and quality of a medicinal
product are not based on the special blue colour or
the angular shape of a tablet. Even the most com-
mon medicinal product is made up of numerous sig-
nificant, standard and specifically designed proper-
ties. Chemically, physically and biologically, a medi-
cinal product is a very complicated invention. Every-
thing about illegal medicinal products is guesswork:
no information is readily available about their com-
position, manufacturing methods. Impurities gener-
ated, diluents used, toxic catalysts or potentially car-
cinogenic constituents will be tested by the users.
Bodies responsible for providing this information
never make an appearance.
One explanation for the change in attitudes to-
wards medicines is a general interest in the differ-
ences in price of medicinal products, i.e. increased
consumer cost-awareness. As a top European coun-
try in Internet use, Finland is an attractive target for
criminals because of the ever increasing number of
Finns having an Internet connection at their dispos-
al. Increasing numbers of Finns use this for making
alterations to their tax returns or are involved in e-
commerce, the on-line buying of a variety of prod-
ucts and services. All of this goes towards increasing
consumers’ confidence in the range of services and
quality on offer in e-commerce.
The belittling attitudes associated with medicinal
product properties are difficult to understand. The
risk associated with illegal trade in medicines is
borne by the purchaser of the medicine alone. It is a
heavy responsibility as one’s own life or that of the
nearest and dearest may be at stake.
We all share the concern for illegal trading in
medicines, fake medicines and measures to fight
against them. The problem is not solved by closing
Internet sites, because the problem lies in human be-
ings themselves and in the blind trust in the faceless
information on offer on the Internet. To raise the
awareness of the members of the public and make
them realise the risks involved with illegal trade of
medicines and counterfeit drugs is an important ef-
fort to educate the public in a situation where the
services and products on offer cannot be abolished.
Jussi Holmalahti
Professor, Head of the Enforcement and Inspection Department
National Agency for Medicines
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Stroke thrombolysis and the chain of recovery
Stroke is the second most com-
mon cause of death following
coronary heart disease (1) and it
causes a greater loss of quality
adjusted life years than any other
disease (2). The incidence and
mortality caused by stroke are
decreasing 2–3% per year in Fin-
land (3), but as our population is
ageing, the number of strokes
and consequently the need for
treatment will double within the
next few decades unless we are
more successful in the prevention
and treatment of stroke (4).
Treatment in a stroke unit de-
creases the stroke patients’ mor-
tality and need for chronic insti-
tutional care, but the aim is to
improve the treatment results
further. This applies especially to
patients with ischemic stroke
since it is the most common
stroke, making up about
75–80% of the total (3, 5-7). A
significant breakthrough was
made in the treatment of acute
ischemic stroke patients with the
development of thrombolysis, in
which also Finland took part (8-
11). Participation in the clinical
trials of thrombolysis ensured
that the treatment is today car-
ried out safely and effectively at
our university and central hospi-
tals.
Thrombolysis is appropriate
in the treatment of acute is-
chemic stroke when it can be ini-
tiated within 3 hours of the on-
set of symptoms, the physician
who provides the treatment is fa-
miliar with the acute treatment of
neurological patients, the patients
are aged between 18 and 80
years, and there are no con-
traindications for the treatment.
When approving thrombolysis
for the treatment of patients with
acute ischemic stroke the EU
health authorities required that
information of all patients who
received thrombolysis with ap-
proved indications should be in-
cluded in an official thrombolysis
register (SITS-MOST) so that the
authorities could monitor the
safety and efficacy of the treat-
ment. According to this register,
the number of stroke patients re-
ceiving thrombolysis in Finland
per one million inhabitants is
greater than in any other EU
country (12). The advantage for
Finland is emphasised even more
if the frequency of the treatment
is compared in the related sister
SITS-ISTR register. This register
also includes information of pa-
tients over 80 and under 18 years
of age who have received throm-
bolysis and those who have re-
ceived it more than 3 hours after
the onset of symptoms, as the ef-
ficacy of the treatment will not
stop at 3 hours provided that the
patients are correctly selected
(11, 13, 14).
According to both the SITS-
MOST and the SITS-ISTR regis-
ters, the neurological emergency
room of Meilahti Hospital pro-
vides a higher number of throm-
bolyses than the two next best
units combined. Tampere ranks
as the third most effective unit in
the registers. Even though it is
not a question of European
championships, this is a signal of
the efficacy of the acute stroke
care in Finland, since, in compar-
ison with the densely populated
countries on the European conti-
nent Finland is scarcely populat-
ed, our towns are small, and the
distance to a hospital providing
thrombolysis is often long.
According to the SITS-MOST
register, the number of patients
receiving early thrombolysis in
Finland is the same as in coun-
tries such as France, Spain or
Italy, where the population is 10-
fold greater than in Finland. The
efficacy of thrombolysis is in di-
rect relation to time: the sooner
the patients are treated the better
are the results. In Helsinki, when
thrombolysis is given within 60
minutes of the onset of symp-
toms, 90% of patients recover
well. In case the treatment is ini-
tiated 90 minutes after the onset
of symptoms, 70% of patients
recover well (15). Of these early
treatments in Finland (within 60,
70, 80 and 90 minutes of the on-
set of symptoms), about 80% are
administered at the neurological
emergency room at Meilahti
Hospital. This can not be ex-
plained only by the fact that the
region of Helsinki is the most
densely populated area in Fin-
land, but first and foremost by
the chain of recovery in which a
Markku Kaste
Professor
Department of Neurology
Helsinki University Central Hospital
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lot of planning and training have
been invested and which there-
fore works well. An ancient tru-
ism applies here: the chain is no
stronger than its weakest link.
The efficacy of thrombolysis is
probably best seen in the results of
basilar artery occlusion, which is
the most devastating stroke. With-
out thrombolysis, 80–90% of
such patients die, and those re-
maining alive are often in lock-in-
syndrome which means that the
only active movement the patient
is capable of is vertical eye move-
ment (16). With the help of throm-
bolysis, mortality is reduced by
40% and 25–30% of the patients
recover well (17). The fact that
thrombolysis is appropriate as
part of routine treatment given to
patients with acute ischemic
stroke and is also effective and
safe outside clinical randomised
trials, is clearly seen in the results
of the recently published SITS-
MOST register (18). Only 1,7%
of those who had received throm-
bolysis developed symptomatic
intracerebral haemorrhage, and
the mortality in those who had
received thrombolysis was lower
than in those recorded in ran-
domised trials, which initially re-
sulted in the approval of the
treatment. The proportion of
those who had recovered well
was 54,8%, which was slightly
higher than that recorded in ran-
domised trials. At this stage the
SITS-MOST register contained
nearly 6,500 patients from al-
most 300 hospitals in the Euro-
pean Union, Norway and Ice-
land, which makes it the largest
data ever published about throm-
bolysis. The register clearly re-
veals that thrombolysis can be
carried out safely and effectively
as part of routine clinical prac-
tice.
Procedure
In order for the treatment to be
safe, the physician providing it
should be familiar with the thera-
peutic indications and contraindi-
cations (Table 1, next page) and
should know how to interpret the
computerised cerebral tomogra-
phy (CT) of the patient taken in
the emergency room (Table 2),
because most hospitals do not
have a neuroradiologist continu-
ously available. A significant
number of Finnish hospitals pro-
viding thrombolysis took part in
the ECASS and ECASS-II studies
(8, 10). In addition, the Finnish
Neurological Society has twice
arranged training on thromboly-
sis in which a German Professor,
Rüdiger von Kummer, who was a
central figure in the development
of the criteria by which patient
selection is made for thromboly-
sis, has given lectures on the in-
terpretation of CT. In association
with these training sessions he
arranged a test for voluntary par-
ticipants. The first test attracted
over 70 neurologists and radiolo-
gists of which more than 80%
achieved good or excellent
marks, a result which Professor
von Kummer had not previously
seen. The good results probably
has contributed to the fact that
thrombolysis has become more
generally used in Finland than in
other European Union countries.
However, good treatment is
not enough without a functional
chain of recovery. In each hospi-
tal district providing thromboly-
sis the organisation of the chain
of recovery has required quite a
lot of motivation, energy, educa-
tion and training, i.e. hard work
from all those involved in the
chain. Based on the SITS-MOST
and SITS-ISTR registers it would
appear that this co-operation is
better managed by Finnish pro-
fessionals than by any other
Union professionals, which
makes you wonder if it is due to
the Finnish team spirit. 
The significance of the chain
of recovery is recognised also in
the USA, where thrombolysis was
approved for the first time in the
world as a treatment for acute is-
chemic stroke. A task force of the
National Institute of Health cre-
ated a model for the various
parts of the chain of recovery,
and this gained approval at a
wide consensus meeting involving
alI parties (19). The model is
largely similar to the one used in
Finland. In the American model
an agreement has been made re-
gionally about which hospital
would provide thrombolysis, af-
ter which everybody involved, in-
cluding the emergency centres
and paramedics, are trained, and
the hospital at which the treat-
ment would be given is allocated
the resources to apply it. It would
be desirable to have the last-men-
tioned feature applied in Finland,
too, as the use of thrombolysis
has not brought additional re-
sources to those hospitals where
it is available, despite the fact
that the treatment requires heavy
Table 2. Once the CT is performed, the following  points should be addressed when a decision
about thrombolysis is to be made for stroke patients.
CT findings indicative of a recent media infarct (within the past 2–6 hours):
• insular cortex not visible 
• the outer edge of the nucleus lentiformis is not visible
• capsula interna not visible 
• difference of sides of the sulci (obliteration) 
• the density of white matter decreased
• the borderline between white and grey matter is not visible
• thrombosis in the main trunk of median cerebral artery (hyperdense MCA sign)
• mass effect (midline shift seen for more than 6 hours)
Preconditions for thrombolysis: 
• normal CT or an infarct developing in less than one third of the territory the MCA
• no haemorrhage found 
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Table 1. Indications and contraindications for thrombolysis in stroke patients
The answer to all questions must be YES
YES NO
Previously independent patient (modified Rankin Scale, mRS 0 - 2)
30 min - 3 hours from the onset of symptoms (basilar thrombosis, up to 48 hours)
A cerebral infarct at the hemispheric level or suspected basilar thrombosis
The patient / near relatives have if possible been informed about the treatment
The answers to all questions must be NO YES NO
Initially a seizure with a loss of consciousness and a strong suspicion of Todd’s palsy
Suspected subarachnoid haemorrhage (SAH)
A history of spontaneous cerebral haemorrhage (excluding SAH if a bleeding aneurysm is closed)
Cerebral infarct within the past 3 months
A history of stroke and diabetes (relative contraindication)
Untreated aneurysm or arteriovenous malformation (relative contraindication)
Known tendency to haemorrhage
A severe haemorrhage, trauma or extensive surgery during the past 3 months
During the past 10 days: external cardiac massage or a puncture of a major vein, which cannot be compressed with
a tightening bandage (e.g. v. subclavia or v. jugularis)
HELLP syndrome (Haemolysis, Elevated Liver enzymes and Low Platelet count)
Pregnancy or a recent delivery (relative contraindication)
Malignant or advanced and extensive cancer
A strong suspicion of endocarditis, septic embolism or pericarditis
Other severe disease or short life expectancy
Intracranial haemorrhage seen on cerebral CT imaging
Is an extensive hypodens area (more than a third of the central cerebral artery vascular area) already to be seen?
Severe cerebral micro-angiopathy
Blood pressure 185/110 mmHg or higher despite treatment
Blood glucose below 2.8 mmol/l or over 22 mmol/l B-gluc
INR over 1.5 or APTT over 60 s or B-thrombocytes < 100
Fast recovery from symptoms
NIHSS 0 - 2
NIHSS > 25/fixed eye deviation + total hemiplegia + reduced level of consciousness
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on-call duties and fast action,
and despite the saving of re-
sources society makes with im-
proved patient recovery (20).
The chain of recovery begins
at the emergency centre, when
the patient, next of kin or any-
body present at the event calls
112. In order for the chain to get
started efficiently, the person in
the emergency centre should be
able to identify a possible acute
stroke patient and send the near-
est ambulance to the patient. The
identification is made easier by
memorising the word FAST,
which is an abbreviation made
up of the words Face, Arm,
Speech and Time. Paramedics
and ambulance personnel are
trained to identify patients poten-
tially appropriate for thromboly-
sis by making a short neurologi-
cal status in accordance with
FAST by asking the patient to
grin, answer some questions and
squeeze with both hands. If the
patient is unable to perform these
functions normally and less than
3 hours have passed since the
start of the symptoms, an ambu-
lance will bring the patient as an
emergency case to the nearest
hospital providing thrombolysis.
When an ambulance embarks on
its transport journey in Helsinki
and its environments, the ambu-
lance staff will phone the emer-
gency room at Meilahti Hospital
for the first time and give an ad-
vance notice of the arrival of a
potential patient for thromboly-
sis. When they are about a 10
minutes’ drive away from the
emergency room they will call the
second time. These advance
warnings make it possible for a
laboratory technician to meet the
patient immediately after his/her
arrival and to take necessary
blood tests, for the CT equip-
ment to be made available, and
for the neurologist to meet and
examine the patient already dur-
ing the transfer to the CT. The
speed at which this all happens is
also significantly increased by the
fact that the CT equipment has
been transferred to the premises
of the emergency room only
about twenty meters distant from
the Meilahti Hospital emergency
room door and that the throm-
bolysis is administered while the
patient is still lying on the CT
table immediately once intracere-
bral haemorrhage and other con-
traindications for the treatment
have been excluded. With this
procedure, door-to-needle time,
i.e. the time from the ambulance
staff opening the emergency
room door to the point where
thrombolysis is initiated, has
been cut from the previous 1.5
hours to less than 25 minutes
(12, 21). Reducing the time by an
hour is decisive for the level of
patient recovery. The motivation
prevailing in all the members of
the chain is reflected, for exam-
ple, by the presence of the para-
medics at the monitor of the CT
of the patient they have brought
in, if their emergency duties al-
low it.
3-hour time window 
Not nearly all stroke patients can
make it to a hospital providing
thrombolysis within three hours
of the onset of their symptoms,
which is when the official time
window closes. Many patients
would nevertheless benefit from
the treatment even after that
(11). These are patients, who af-
ter three hours have cerebral tis-
sue, which is suffering from the
shortage of oxygen but have not
yet infarcted and is thus available
for rescue if the occluded artery
can be opened early enough.
These patients could be identified
by modern magnetic resonance
imaging (MRI). According to re-
cent studies, it was possible to
open about 70% of the occluded
cerebral arteries in these patients
by using desmoteplase, and of
those in whom it was possible to
open the blocked cerebral artery
about 60% recovered well with
thrombolysis which was initiated
within up to nine hours of the
onset of symptoms (13, 14). Fin-
land took part in the study car-
ried out in Europe (13). The MRI
equipment used in these studies is
available in all university hospi-
tals and most central hospitals in
Finland.
A large international multicen-
ter study, ECASS-III, is ongoing
in which an attempt is being
made to extend the time window
to 4.5 hours. The study was
launched by a requirement of the
European Union health authori-
ties. The study will be concluded
this year and then it will become
clear whether the time window
can be extended to 4.5 hours.
Since Finland takes part also in
this study, the results, once ready,
will be very appropriate for im-
plementation in the treatment of
Finnish ischemic stroke patients.
The selection of patients in the
ECASS-III study is made by using
CT equipment which can be
found in all major hospitals with
an emergency room.
Stroke Unit
After thrombolysis the patient’s
follow-up treatment is executed
in a stroke unit. According to the
Finnish recommendations, the
need for rehabilitation of all
stroke patients is assessed, the
reason and risk factors for stroke
are diagnosed, and the treatment
of risk factors including sec-
ondary prevention and early re-
habilitation, is initiated in a
stroke unit, and any necessary
follow-up rehabilitation is ar-
ranged either at a rehabilitation
hospital or in an out-patient clin-
ic (22).
Irrespective of whether it is
possible to provide thrombolysis
and whether it is successful,
treatment in a stroke unit is
strongly recommended, because it
reduces both mortality and the
risk for chronic institutional care
as well as improves the patient’s
chance for a good recovery (23,
24). Stroke unit care will max-
imise not only the results
achieved with thrombolysis, but
also the secondary prevention
and rehabilitation of those pa-
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tients who were not eligible for
thrombolysis or who did not get
it for other reasons. Treatment
results achieved in a stroke unit
last for at least 10 years (25).
Other recanalisation therapies
Thrombolysis is usually carried
out with intravenous alte-plase. If
this does not open the artery, the
treatment can be continued with
intra-arterial thrombolysis. It
may sometimes be justified to
start intra-arterial thrombolysis
straight away (26, 27). This is es-
pecially true in stroke patients
with extensive clots, such as in a
case where the entire carotid
artery and middle cerebral artery
are occluded, or the entire basilar
artery is occluded. Such huge
clots do not often open up with
intravenous thrombolysis. Efforts
have been made to improve re-
canalisation with extracranial ul-
trasound (28) and ongoing stud-
ies intend to improve the efficacy
by in addition to extracranial ul-
trasound giving the patient intra-
venous microbubbles (29).
As with coronary heart dis-
ease, mechanical recanalisation
therapies have also been devel-
oped for the treatment of ischem-
ic stroke. These involve a catheter
which is inserted in the artery
and by which efforts are made to
remove the clot the same way as
a cork from a bottle of wine is re-
moved (30). The U.S. Food and
Drug Administration (FDA) has
already approved this type of
equipment for clinical use. As a
result, the mechanical removal of
a clot by using such equipments
is rapidly increasing in the USA,
but additional proof on whether
it improves the outcome of pa-
tients is required. For assessing
the results, efficacy and safety of
the therapy a register known as
the MERCI register has been set
up in the USA in which all pa-
tients given this therapy are en-
tered. Experience of this therapy
has already been gained in Fin-
land and Sweden as well, and the
two countries are about to join
the register.
Telestroke
When the availability of throm-
bolysis, which is the only effec-
tive medical treatment for acute
ischemic stroke, is used to evalu-
ate the quality of treatment of
stroke at the population level,
Finland is the most efficient
country in the European Union.
The high level of stroke treatment
in Finland was also shown in a
survey carried out by means of a
questionnaire which was sent to
randomly selected hospitals in the
EU member states. A total of 886
hospitals completed and returned
the questionnaire. The survey
showed that the treatment of
stroke patients was best organ-
ised in Finland, Sweden, the
Netherlands and Luxembourg
(31). But even so, there is great
inequality in the availability of
thrombolysis also in Finland. In
the smaller central hospitals and
the still smaller rural hospitals,
except at Kuusankoski Hospital,
the treatment is not available
even during office hours. This in-
equality could be greatly reduced
by the means of telemedicine. At
present X-rays, CT imaging and
MRI results are transferred elec-
tronically in real time from one
hospital to another, and video im-
ages and sound can also be trans-
ferred in real time. By using these
communications a patient and a
doctor at a smaller hospital and a
doctor at a larger university hos-
pital can be in direct visual and
speech contact with each other
and at the same time examine the
results of laboratory tests, CT
and MRI performed at the small-
er hospital. The neurologist at the
university hospital experienced in
thrombolysis and in the treatment
of stroke patients can help the
colleague in the smaller hospital
in the choice and carrying out of
the treatment, thereby making
thrombolysis possible even in the
smaller hospital. A fair amount
of experience has already been
gained about the use of telestroke
(32-36).
When projects for the national
health programme were selected a
few years ago, Helsinki and Uusi-
maa hospital district proposed
telestroke as a nationwide pro-
ject, but it did not reach the level
of a financed project. The tele-
stroke project, in which Helsinki
University Central Hospital sup-
ports smaller hospitals in their
decisions on thrombolysis, was
nevertheless launched when the
State Provincial Office of South
Finland decided to collaborate in
the project by undertaking to pay
half of the funding required, the
other half of which was provided
by the hospital districts of Helsin-
ki and Uusimaa, Etelä-Karjala
and Kymenlaakso. Time is of the
essence in thrombolytic treat-
ment, and therefore it is signifi-
cantly wiser to transfer know-
how than the patient from one
hospital district to another. With
the help of telestroke and the old
Finnish team spirit, support has
also been given to the central
hospitals of Lapland and Länsi-
Pohja. According to the basic
principles of Finnish society it is
important that all Finns have
equal opportunity for thromboly-
sis. This challenge would be pro-
moted by having the telestroke
system cover all hospital districts
in the country. When the treat-
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ment increases the patient’s possi-
bilities to return to normal life in
good condition, it is the only hu-
manly correct alternative. Oper-
ating telestroke is also economi-
cally a sound choice because it
generates significant savings for
society (20). The same conclusion
has apparently been drawn in the
USA, as the American Heart As-
sociation has set up a task force
to write a national recommenda-
tion for telestroke. Finland is tak-
ing part in this task force.
Communication
Even the most effective acute
treatment is of no benefit if pa-
tients do not seek for help in
time. In myocardial infarction se-
vere pain makes the patient look
for help immediately. At the pop-
ulation level there is also evident-
ly high awareness of the serious-
ness of coronary heart disease
and of the fact that treatment is
available. Even though good
treatment for acute ischemic
stroke is now available, the
knowledge of it is not widely
spread among the population. It
is still a very common belief that
when a stroke occurs there is
nothing to be done, so why rush
– especially when the condition is
generally not painful. Usually the
numbness and weakness of a
hand is just being “watched” and
treatment is not sought early
enough. Few people know that
thrombolysis in ischemic stroke is
more effective than it is in coro-
nary heart disease, and the differ-
ence to the advantage of throm-
bolysis in stroke grows in line
with the speed at which it is ad-
ministered (37). This is not well-
known even among physicians,
which may partly explain why
the treatment has not been set up
quickly in every hospital district
in Finland despite the clear in-
structions given in the recently
published Current Care Recom-
mendation about how the treat-
ment should be carried out (22).
Conclusion
Thrombolysis is here to stay. It is
aimed at the fast opening of the
occluded cerebral artery and
thereby at the prevention or at
least alleviation of a brain infarc-
tion, which would otherwise de-
velop. Further studies will help to
prolong the time within which
the treatment can be adminis-
tered, and new, more effective
drugs will be developed for re-
canalisation of occluded brain ar-
teries, including invasive treat-
ments of the type of balloon an-
gioplasty of coronary thrombosis.
Developments in the imaging
techniques will improve the selec-
tion of patients who would bene-
fit from the treatment. Passively
waiting for this development to
happen is not acceptable; treat-
ment for the population should
be arranged NOW (12, 38).
Thrombolysis is the best avail-
able treatment, even though it is
not appropriate for all patients
with acute stroke. All patients
would nevertheless benefit from a
fast transportation to a hospital
with a stroke unit and where
thrombolysis is available. Even
though thrombolysis in Finland is
given to more patients per one
million inhabitants than in any
other country in the European
Union, we are not in an equal po-
sition to have thrombolysis when
needed. This could be immediate-
ly improved by arranging a chain
of recovery for acute stroke pa-
tients and by facilitating decision-
making in smaller hospitals with
the aid of telemedicine. The
knowledge about acute stroke
among the population and about
the fact that it is possible to re-
cover from it should also be in-
creased, as well as of the fact that
the possibilities of recovery are
crucially improved by fast admin-
istration of thrombolysis.
See literature on pages 9-10.
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Adverse drug reactions in the elderly
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This article discusses adverse re-
actions in those aged 75 years or
more. Vaccines are excluded from
the discussion. Since 1973 and
until the end of 2006, the adverse
drug reaction (ADR) register of
NAM has received a total of
2,131 reports of such reactions.
During the past 10 years the
number of reports has varied be-
tween 75 and 122 annually, with
reports on serious ADRs account-
ing for 52–74%.
The majority have concerned
the youngest members of that age
group, more often involving
women (72 %) rather than men
(28 %) (Fig. 1). The oldest per-
son involved was a 98-year-old
woman who developed serious
thrombocytopaenia and petechiae
(small capillary haemorrhages of
the skin) immediately following
the introduction of ofloxazine
therapy.
The number of drugs under
suspicion totalled 2,331 (one re-
port may include more than one
suspected drug). By far the largest
number of reports concerned an-
ti-infectives for systemic use
(674), followed by cardiovascular
system drugs (376), nervous sys-
tem drugs (366) and drugs for the
treatment of musculo-skeletal dis-
orders (296). The reports received
are detailed by groups of drugs in
the Table. Skin was the most af-
ten affected organ (17% of ad-
verse reactions, Fig. 2)
Anti-infectives for systemic
use
The majority of reports on anti-
infectives were about nitrofuran-
toin (201), sulphonamide and
trimethoprim products (119) and
the fluoroquinolones (96). A total
of 147 reports on nitrofurantoin
described pulmonary adverse re-
actions. The usual manifestations
on chest x-ray were infiltrates or
fibrosis associated with the symp-
toms of dyspnoea and cough, and
often combined with fever. If ni-
trofurantoin therapy is consid-
ered necessary in an elderly pa-
tient, the symptoms should be
carefully monitored and treat-
ment discontinued immediately
upon the onset of symptoms in-
dicative of nitrofurantoin lung.
Adverse hepatic reactions caused
by nitrofurantoin were described
in 14 of the reports. Further re-
ports concerned fever as an iso-
lated symptom, and cases of rash,
nausea and vomiting.  
There were 42 reports on
trimethoprim, 33 on the combi-
nation of sulfadiazine and trim-
ethoprim and 30 on the combina-
tion of sulfamethoxazole and
trimethoprim. Of the reports on
trimethoprim, 25 concerned vari-
ous skin symptoms, some of
which were serious (3 cases of the
Stevens-Johnson syndrome and
one of epidermal necrolysis).
Changes in the blood count, such
as thrombocytopaenia and
leukopaenia, were reported on 11
occasions. Adverse reactions
caused also by sulphonamide-
trimethoprim combination prod-
ucts were expressed mainly in the
skin and bone marrow. The peri-
od of exposure from the start of
the treatment to the discovery of
the adverse effect on the bone
marrow varied from days to
months.
Cephalosporins were reported
on in 69, penicillins in 52 and
macrolides in 18 reports. Ceph-
alosporins were most commonly
reported on owing to diarrhoea
associated with the use of ce-
furoxime (14), often that due to
Clostridium difficile. Skin symp-
toms were also common with the
use of cephalosporins as well as
with penicillin therapy. Half of
the adverse reactions caused by
macrolides were expressed either
in the skin or the liver. Drugs
used in the treatment of tubercu-
losis were reported on 50 times;
there were 17 reports each on ri-
fampicin and isoniazide, and 12
reports on ethambutol. The most
common effects of ethambutol
were on the eyesight (11 reports),
The elderly exhibit the same adverse reactions as younger adults do, but owing to changes in the
pharmacokinetics of drugs, for example, the elderly may be more sensitive to reactions. Recognising
the adverse reactions may be difficult, because they may be considered to be symptoms associated
with old age or a disease. Multitherapy, which is usual in the elderly, may make it difficult to recog-
nise the association between the drug used and the adverse reaction caused. The adverse reaction in
an elderly person may be more serious than in a younger person and the time of recovery from an ad-
verse reaction may be longer. For example, it may take a considerably longer time to learn to walk fol-
lowing recovery from an Achilles tendon injury caused by fluoroquinolone.
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where the most common adverse
reaction was optic neuritis with
subsequent discontinuation of
treatment necessary in order to
avoid permanent damage to the
sight.
It is interesting to note that
oral terbinafine (classified as a
dermatological) attracted 15 re-
ports, but other systemic antifun-
gals were only reported on 9
times in all. All adverse reactions
caused by terbinafine involved
the skin with one report also
mentioning a loss of the sense of
taste, which is a well-known ad-
verse effect of this drug. The
sense of taste is usually restored
after discontinuation of the ther-
apy. In the long term this com-
plaint may result in weakening
of the nutritional state in the el-
derly.
Cardiovascular system
ACE inhibitors were reported on
80 times and angiotensin recep-
tor blockers 22 times (including
combination products containing
diuretics). Medicinal products
containing enalapril were respon-
sible for 45 reports and captopril
for 21. The most common ad-
verse reactions with these were
cough (20), angio-oedema (10)
and blood count changes (10)
such as agranulocytosis. Diuret-
ics were reported on in 54 re-
ports, most of which being about
a combination of hydrochloro-
diazide with a potassium-sparing
diuretic (19). The majority of the
51 reports received on calcium
inhibitors concerned diltiazem
(28), the adverse reactions
caused by which were almost all
about skin symptoms. Beta-
blockers attracted 37 reports in
all.
Among statins (44 reports in
total), atorvastatin was the one
most commonly reported on (17)
followed by simvastatin (11).
Various degrees of muscular (16)
and liver (13) reactions were re-
ported as expected. Muscular ef-
fects can be difficult to identify
in the elderly if both the doctor
and the patient consider them to
be associated with the general
frailty that comes with age. Inter-
actions increase the risk of statin-
induced adverse reactions. For
example, the combined use of
clarithromycin (500 mg/day) and
simvastatin (80 mg/day) in an
85-year-old female was associat-
ed with rhabdomyolysis and a
10-fold elevation of the liver en-
zymes. These drugs were discon-
tinued and the patient recovered.
Clarithromycin is a CYP3A4 in-
hibitor and simvastatin is its sub-
strate. In another case, a 77-year-
old male had been prescribed
oral fluconazole (150 mg/day)
and atorvastatin (40 mg/day),
the metabolism of which is medi-
ated by CYP3A4. The patient
developed rhabdomyolysis and
multiple organ failure, to which
he succumbed.
There were isolated cases of
drugs used in the treatment of
cardiovascular diseases receiving
more than 10 reports: amiodar-
one (15) and methyldopa (15).
Digoxin was involved in 9 re-
ports, most of which were about
cardiac effects. The effects of
digoxin are potentiated in the el-
derly due to impaired renal func-
tion. Several of the important in-
teractions of digoxin are mediat-
Fig. 1. ADR reports according to  age and sex.
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ADR reports in the elderly since 1973 divided into drug groups. Number of 
reports
Anti-infectives for systemic use 674
Cardiovascular system 376
Nervous system 366
Musculo-skeletal system 296
Blood and blood-forming organs 116
Antineoplastic and immunomodulating agents 100
Respiratory system 45
Other 44
Genito-urinary system and sex hormones 39
Sensory organs 37
Dermatologicals 36
Systemic hormonal preparations (excl. sex hormones and insulins) 33
Antiparasitic products, insecticides and repellants 9
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ed by p-glycoprotein. One report
described a 76-year-old male who
developed bradycardia, oedema,
tiredness and an elevated serum
digoxin concentration subsequent
to the introduction of itracona-
zole, a p-glycoprotein inihibitor,
in adjunct therapy with digoxin.
On discontinuation of itracona-
zole therapy the digoxin concen-
tration was restored to a normal
therapeutic level and the symp-
toms disappeared.
Drugs affecting nervous 
system
Among affecting nervous system,
most of the adverse reactions re-
ported concerned antiepileptics
(58) and antipsychotics (54). The
most frequently reported
antiepileptics were carba-
mazepine and pregabalin (both
received 16 reports) and pheny-
toin (14). The majority of these
adverse reactions were skin reac-
tions. In addition to epilepsy, pre-
gabalin is also used in the treat-
ment of neuropathic pain. Ten of
the adverse reactions it caused in-
volved the nervous system or the
psyche; patients for example ex-
perienced confusion. It is essen-
tial to start treating the elderly
with an adequately low dose (e.g.
25 mg of pregabalin twice a day)
and to monitor the response and
any adverse reactions manifested.
Cholinesterase inhibitors, used
in the treatment of Alzheimer’s
disease, were involved in 41 re-
ports, donepezil in 20, rivastig-
min in 16 and galantamine in 5
reports. These reports were main-
ly about bradycardia or atrioven-
tricular block (10), digestive tract
symptoms, such as vomiting and
diarrhoea (10) and adverse effects
on the liver (3). Reports received
on anti-Parkinson drugs num-
bered 28, most of them on
bromocriptine, all 7 reports on
which described various fibrotic
pulmonary or pleural manifesta-
tions.
Antipsychotics attracted a to-
tal of 54 reports (most of them,
7, on risperidone) and sedatives
and hypnotics a total of 16
(mostly on zolpidem, 5). Opioids
were involved in a total of 27 re-
ports with tramadol as the one
most commonly reported (15).
Nine of the reports on tramadol
described adverse reactions on
the nervous system and the psy-
che, such as confusion and hallu-
cinations.
Among antidepressants the
one most frequently reported was
mianserin, and 38 of its total re-
ports of 46 were about blood
count changes, most commonly
about leukopaenia of various de-
grees of severity. Blood count
changes were also described in 8
of the total of 17 reports on mir-
tazapine. The SSRI drugs attract-
ed 29 reports, most of them on
citalopram (15) with the most
commonly reported single ad-
verse reaction caused being hy-
ponatraemia (4).
Musculo-skeletal system
Among the drugs for the treat-
ment of musculo-skeletal disor-
ders the majority of reports were
about anti-inflammatory anal-
gesics, with the biggest group be-
ing the coxibs (64 reports). Propi-
onic acid derivatives (ibuprofen,
naproxen and ketoprofen) re-
ceived a total of 38 reports, fena-
mates 17, indomethacin 15 and
diclofenac 13. Of the 20 reports
on celecoxib eight involved an
adverse skin reaction, and three
reports described a gastrointesti-
nal haemorrhage. Celecoxib is
structurally a sulphonamide and
it must not be prescribed for pa-
tients who are allergic to sulpha.
Of the 13 reports on etoricoxib
three described cardiac failure,
and two duodenal ulcer. There
were 28 reports received on
nimesulide, which has been with-
drawn from the market by now,
the majority (21) of which were
on adverse effects on the liver
(during 1999–2002). Stomach or
duodenal ulcer was reported
three times.
Twenty-six reports were re-
ceived on allopurinol, and 30 on
bisphosphonates. Fifteen of the
adverse reactions caused by al-
lopurinol were about various
changes in the blood count, most
commonly about agranulocytosis,
and skin reactions numbered 10.
The majority of reports on bis-
phosphonates involved oral alen-
dronate (16), which most com-
monly caused oesophageal or
stomach ulcers (6) or arthralgia
(2). To prevent ulcers in the up-
per digestive tract, users of alen-
dronate should be carefully in-
structed to ensure correct intake
Psychiatric disorders
3 %
Nervous system
disorders
6 %
Hepato-biliary
disorders
6 %
Cardiac and vascular
disorders
5 %
Musculoskeletal,
connective tissue and
bone disorders
3 %
Infections and
infestations
3 %
Gastrointestinal
disorders
9 %
Respiratory disorders
9 %
Eye and ear disorders
3 %
Skin and
subcutaneous tissue
disorders
17 %
General disorders and
administration site
conditions
14 %
Blood and lymphatic
system disorders
12 %
Other
10 %
Fig. 2.  Reported adverse drug reactions according to SOCs .
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of the drug. Five of the seven re-
ports on intravenous zoledronic
acid described osteonecrosis (of
the jaw), which can impair the
quality of life. To reduce the risk,
patients should have their teeth
examinded and treated before the
introduction of zoledronic acid
therapy.
Alimentary tract and 
metabolism
Reports on the drugs for the
treatment of diseases involving
the alimentary tract and metabo-
lism involved biguanides (27 re-
ports, 17 of which were on met-
formin and 10 on fenformin,
withdrawn from the market
since) and sulphonylureas (27).
Among the reports on met-
formin, 10 concerned lactic aci-
dosis, and the majority of reports
on sulphonylureas concerned hy-
poglycaemia. Lactic acidosis is a
very rare adverse reaction, but
the risk is increased in the elderly
and those suffering from malnu-
trition. Similarly, hypoglycaemia
is more readily developed in the
elderly with reduced renal func-
tion. The hypoglycaemic effect of
glibenclamide is also prolonged,
because of the accumulation of
its active metabolite in the body.
Sulphasalazine was reported
on 19 times, the majority of cas-
es were about blood count
changes (12) most commonly in-
volving agranulocytosis. Also the
majority (11) of the total (18) re-
ports on the metamizole-pitofen-
one combination product were
about an adverse effect on the
leukocytes. Because of the risk of
agranulocytosis, the necessity for
using metamizole ought to be
considered carefully. Patients
should also be given clear in-
structions to discontinue their
medication and to seek immedi-
ately for medical advice when
symptoms indicative of agranulo-
cytosis (such as fever, sore throat
and malaise) occur.
Proton pump inhibitors were
the subject of 15 and H-2 block-
ers of 12 reports, with the ad-
verse reactions caused by these
manifested in various organ sys-
tems.
The blood and blood-forming
organs
Among drugs used in treatments
involving the blood and blood-
forming organs, warfarin was re-
ported on 41 times. Of these re-
ports, 33 described some haem-
orrhages, 12 of which were fa-
tal. The most usual haemor-
rhages were intracranial (12) or
gastrointestinal (8). Of the in-
tracranial haemorrhages four
were intracerebral, the risk of
which is greater in the elderly re-
ceiving warfarin therapy than
younger patients. The remaining
8 cases involved subdural haem-
orrhage, with the common de-
nominator that generally there
was no knowledge of any expo-
sure to injury. The most com-
mon interaction was an increase
in the INR associated with
CYP2C9 inhibition and caused
by miconazole oral gel (4 re-
ports). The elderly may have dif-
ficulties in managing the INR
monitoring. One 82-year-old fe-
male had continued to take war-
farin without INR monitoring,
as the intention was to discon-
tinue the medication, but the pa-
tient accidentally continued it.
As a consequence, she suffered
gastrointestinal haemorrhage
which ended fatally. There was
another case where the exces-
sively high INR value causing a
haemorrhage in a 79-year-old fe-
male was the result of an “acci-
dental interruption in the INR
monitoring”.
Fourteen reports were re-
ceived on heparins and 30 re-
ports on other coagulation in-
hibitors, the majority on low-
dose acetylsalicylic acid (8),
clopidogrel (7) and dipyridamol
(6). Alteplase was the object of
13 reports with the most com-
mon adverse reaction being in-
tracerebral haemorrhage (8) in
patients where the therapeutic
indication had been cerebral in-
farct. One report also described
an 80-year-old male who, after
having received alteplase for the
treatment of myocardial infarc-
tion, suffered haemorrhage in the
choria of both eyes and was per-
manently blinded.
Other
Among the reports on anti-can-
cer drugs and immunomodula-
tors, more than 10 concerned
methotrexate (27) and azathio-
prine (10). In the other drug
groups, over 10 reports were re-
ceived on tamsulosin (20), car-
bimazole (19), iopromide (17)
and verteporfin (11). The most
common adverse reaction caused
by tamsulosin, used for benign
prostate hyperplasia, was IFIS
(Intraoperative Floppy Iris Syn-
drome) associated with alpha
blockage and making cataract
operation difficult (16). All the
reports on carbimazole, used for
the treatment of hyperthy-
roidism, were about granulocy-
topaenia. Iopromide, a computer
tomography contrast medium,
caused various hypersensitivity
reactions, such as rash, nausea
and anaphylactic reactions (4).
Verteporfin is used as a photo-
sensitising agent in the treatment
of retinal degeneration in the el-
derly and its typical adverse ef-
fect is back pain, on which 9 re-
ports were received.
Adverse reactions in the 
elderly 
A 75-year-old male developed in-
somnia and agitation after the in-
troduction of scopolamine eye
drops. The medication was dis-
continued, but the patient had
not yet recovered 5 days later
when the report was made.
Scopolamine is an anticholinergic
which is used in iritis to dilate
the pupil. It can cause adverse re-
actions, such as dry mouth, con-
stipation and micturition prob-
lems owing to the muscarine re-
ceptor blockage. CNS effects are
rare, but possible.
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After the introduction of med-
ication with tramadol (100
mg/day), a 77-year-old female ex-
perienced four nocturnal events
of loss of consciousness, once
while she was standing up and
three times causing her to fall off
a chair. She subsequently experi-
enced chest pain and numbness
in the left hand. After discontinu-
ation of the tramadol therapy no
more attacks occurred. The el-
derly in particular are sensitive to
the adverse effects of tramadol,
e.g. dizziness. The treatment
should therefore be introduced
using a small dose and monitor-
ing the response and adverse re-
actions; a therapeutic dose lower
than that in the younger patients
may be adequate (e.g. 50–150
mg/day).
Donepezil therapy introduced
in a 79-year-old male (at a daily
dose of 5 mg) had to be with-
drawn after a couple of months
of use, because during the entire
duration of the therapy the pa-
tient (or his wife, rather) was
troubled by excessive hypersexu-
ality. The symptom disappeared
following discontinuation of
donepezil.
A 79-year-old female, who
had been using ramipril (at a dai-
ly dose of 10 mg) for about three
months, started vomiting and de-
veloped dizziness and arrhyth-
mia. She was diagnosed as hav-
ing renal failure and hyper-
kalaemia. Ramipril was discon-
tinued and the patient was treat-
ed with Resonium (a cation ex-
changer) and fluid therapy. She
had not yet recovered at the time
of the report being made. ACE
inhibitors reduce the renal func-
tion in particular if the patient is
poorly hydrated, e.g. in associa-
tion with diarrhoea or a feverish
infection. Anti-inflammatory
analgesics have the same effect. 
An 80-year-old female had
used a combination product of
metamizole and pitofenone as
necessary over a couple of years,
when she developed fever. Agran-
ulocytosis with associated septic
infection was diagnosed. She was
treated with broad spectrum an-
tibiotics and leukocyte growth
factors. The patient recovered
from angranulocytosis, but her
general condition and ability to
move about were impaired dur-
ing hospitalisation. It was not
possible to discharge her to her
previous care home, and she was
consequently transferred to a
healthcare centre department for
follow-up treatment.
An 80-year-old female was re-
ceiving diclofenac for her joint
symptoms; the other drugs in-
cluded clonazepam, alendronate
and zopiclone. The patient expe-
rienced an event of unconscious-
ness of some type. Jaundice and
elevation of transaminase and
bilirubin values were discovered
at this stage. Infections and au-
toimmune diseases were exclud-
ed. A liver biopsy finding was in-
dicative of a drug-induced liver
damage, the most likely culprit
being diclofenac. All therapies
were discontinued for a time and
a course of prednisolone was in-
troduced. Transaminase and
bilirubin values dropped during
follow-up after which alen-
dronate therapy was reinstated.
An 82-year-old male was
started on zolpidem therapy at a
dose of 10 mg administered in
the evening. This was followed
by the occurrence of nocturnal
sleepwalking, hallucinations, odd
dreams, and the patient was also
said to have “talked strangely”.
The symptoms disappeared on
withdrawal of the therapy.
A 84-year-old male had used
warfarin for atrial fibrillation for
several years, when he developed
a possible case of “purple toe”
syndrome: his toes turned purple
and were painful. The symptoms
disappeared when warfarin was
put on hold owing to a dental
procedure, and the symptoms re-
curred when the medication was
reintroduced. The symptoms dis-
appeared when warfarin therapy
was withdrawn altogether. The
symptoms are thought to have
developed during warfarin thera-
py when the blood seeping into
the atherosclerotic plaque sends
into the circulating blood small
cholesterol emboli which subse-
quently become impacted in the
smaller vessels.
An 85-year-old female was
started on trimethoprim therapy
(at a daily dose of 300 mg). Fol-
lowing the intake of the first
tablet she was feeling unwell and
developed fever and experienced
confusion. Her level of con-
sciousness dropped and she had
to be intubated. She was diag-
nosed with aseptic meningitis,
which recurred when trimetho-
prim therapy was reintroduced in
hospital. After discharge from
hospital she was accidentally ex-
posed once more to trimethoprim
and was hospitalised again the
following morning owing to re-
duced consciousness. Aseptic
meningitis is a well-known, albeit
rare, adverse reaction caused by
trimethoprim.
An 87-year-old male devel-
oped visual hallucinations fol-
lowing the introduction of clopi-
dogrel therapy (at a daily dose of
75 mg). He saw non-existing ani-
mals, ants and people. The pa-
tient recovered after discontinua-
tion of the therapy. Similar symp-
toms (confusion and hallucina-
tions) have been described occa-
sionally in patients on clopido-
grel therapy.
A 95-year-old male became
restless following introduction of
ciprofloxacin therapy (at a daily
dose of 500 mg).  Suicidal behav-
iour also emerged. The patient
was unable to describe why he
felt so bad and was so restless.
The symptoms disappeared after
discontinuation of the medica-
tion. Various psychiatric symp-
toms, such as anxiety, depression,
hallucinations and even psychotic
reactions, which may be associat-
ed with suicidality, are well-
known, but luckily rare, adverse
reactions induced by fluoro-
quinolones.
The Finnish National Agency for
Medicines is improving its medic-
inal product information service.
The service is available on
NAM’s website at www.laake-
laitos.fi or www.nam.fi by click-
ing in the right hand corner of
the first page at Medicines/
NamWebSearch.
Information can be found
about medicinal products for hu-
man use, veterinary medicinal
products, herbal medicinal prod-
ucts, products of parallel import
and parallel distribution as well
as, for example, information
about medicinal products with a
deleterious effect on driving in
traffic. The service provides de-
tails of whether a certain medi-
cine is on the market or whether
its marketing authorisation has
been withdrawn.
The first page of the service
provides an additional new
search option, by the name of the
marketing authorisation holder.
The search can also be restricted
to include either medicines for
human use or veterinary medici-
nal products exclusively (Fig. 1).
The new service will in future
also provide information about
the variations made in the mar-
keting authorisations.
The link Other queries opens
up a page containing information
about the following amendments
• trade names
• marketing authorisation
holder
• prescription/dispensing con-
dition
• prescription status
The search period can be lim-
ited to include a desired period
only (Fig. 2).
The links previously provided
on the fist page List medicinal
products that may impair the
ability to drive and use machines
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NamWeb – the medicinal product information service is being 
improved
Fig. 1.
Fig. 2.
– and List all medicinal products
covered by a prescription/dis-
pensing condition have been
moved to the page ‘Other
queries’. 
This service also allows a
search for those medicinal prod-
ucts which contain a new active
substance (a new medicinal sub-
stance). NamWeb will show a list
of those products which have
within the past 12 months been
granted a marketing authorisa-
tion while containing a new ac-
tive substanceor new medicinal
compination. The novelty is
shown separately for medicinal
products for human use and vet-
erinary medicinal products, ac-
cording to the ATC Code and
first authorisation date of the
product. 
The following changes have
been made concerning medicinal
products where information
about the individual product is
to be found. Following classifica-
tions have been added (Figs. 3
and 4)
• Product for parallel distribu-
tion
• Herbal medicinal product
The search service shows both
the current and the previous
names (Fig. 5). The information
is found both on the first page by
clicking at ‘Medicines and on the
page for ‘Other queries’ when
searching for changes of trade
names. If the name has not been
changed, the section ‘Previous
trade names’ is blank.
Leila Mälkönen
TABU 5. 200764
In English
Fig. 3.
Fig. 4.
Fig. 5.
